Experimental ALS therapy shows promise in phase 1 trial; patient study set
The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good safety profile.| ALS News Today
The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good safety profile.| ALS News Today
Coya Therapeutics got FDA clearance for a Phase 2 trial in the U.S. to investigate COYA 302 as an ALS treatment.| ALS News Today
Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Previously, she has written about science for The Dallas Morning News and the...| ALS News Today
Category archive page for News.| ALS News Today
